Stephens Consulting’s Anixa Biosciences ANIX Stock Holding History

Stephens Consulting’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$3.12K	Hold	1,000	–	–	﹤0.01%	325
2025 Q3	$3.3K	Hold	1,000	–	–	﹤0.01%	298
2025 Q2	$3.3K	Hold	1,000	–	–	﹤0.01%	436
2025 Q1	$2.86K	Hold	1,000	–	–	﹤0.01%	416
2024 Q4	$2.32K	Buy	+1,000	New	+$3.1K	﹤0.01%	456

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MWM

Mission Wealth Management Santa Barbara, California $4.86B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Stephens Consulting's ANIX Position: Q4 2025 in Review

Stephens Consulting held its Anixa Biosciences (ANIX) position steady in Q4 2025 at 1,000 shares worth $3.12K. The position accounts for ﹤0.01% of the portfolio, ranked #325.

Stephens Consulting first reported a position in ANIX in Q4 2024 and has held it in 5 quarters since. The position peaked at $3.3K in Q3 2025. 71 funds tracked by Wall St. Rank hold ANIX as of Q4 2025.

Stephens Consulting held 1,000 shares of Anixa Biosciences worth $3.12K as of Q4 2025.
Stephens Consulting left its Anixa Biosciences share count unchanged in Q4 2025.
Anixa Biosciences made up ﹤0.01% of Stephens Consulting's portfolio in Q4 2025, its #325 holding.
Stephens Consulting first reported a position in Anixa Biosciences in Q4 2024 and has held it in 5 quarters since.
Stephens Consulting's Anixa Biosciences position peaked at $3.3K in Q3 2025.
71 funds tracked by Wall St. Rank held Anixa Biosciences as of Q4 2025.

Based on Stephens Consulting's 13F filing for Q4 2025, filed 13 Jan 2026.